Karyopharm Therapeutics (KPTI) Tops Q4 EPS by 95c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of $0.46, $0.95 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $126.3 million versus the consensus estimate of $50.49 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
• Goldman Sachs starts Viridien at Buy on exploration recovery, shares rise
• Helix and Hornbeck complete all-stock merger, form new NYSE: HOS